63,000 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Meitav Investment House Ltd.

Meitav Investment House Ltd. bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 63,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,606,000.

Other large investors have also recently made changes to their positions in the company. Whittier Trust Co. bought a new position in Halozyme Therapeutics during the 1st quarter valued at approximately $27,000. GAMMA Investing LLC grew its position in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in Halozyme Therapeutics in the second quarter worth about $49,000. Finally, Fidelis Capital Partners LLC purchased a new position in Halozyme Therapeutics in the first quarter worth about $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 0.1 %

NASDAQ:HALO opened at $50.65 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $33.07 and a one year high of $65.53. The business has a fifty day moving average price of $57.56 and a 200-day moving average price of $51.83. The firm has a market capitalization of $6.45 billion, a price-to-earnings ratio of 20.90, a price-to-earnings-growth ratio of 0.50 and a beta of 1.27. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.68 earnings per share. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $35,583,199.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now directly owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,881 shares of company stock valued at $5,169,834. Company insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, October 25th. TD Cowen increased their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Finally, The Goldman Sachs Group boosted their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $60.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.